FrancophonIA/ELRC3.0 huggingface dataset:
English: If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.
Slovenian: Če je potreben centralni venski kateter (CVK), je treba upoštevati tveganja povezana z zapleti s CVK vključno z lokalnimi okužbami, bakteriemijo in trombozo na mestu katetrizacije.
English: AUC0-inf (h*IU/dl)
Slovenian: AUC0-inf (h*i.e./dl)
English: It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.
Slovenian: Zavedati se je treba, da imajo bolniki z inhibitorji faktorja IX povečano tveganje za anafilaksijo pri naslednji izpostavitvi faktorju IX.
English: Driving and using machines IDELVION does not effect your ability to drive and use machines.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Zdravilo IDELVION nima vpliva na sposobnost vožnje in upravljanja strojev.
English: Place the powder vial on an even and firm surface.
Slovenian: Postavite vialo s praškom na ravno in trdno podlago.
English: Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.
Slovenian: Bolnike moramo poučiti o zgodnjih znakih preobčutljivostnih reakcij, ki vključujejo koprivnico, generalizirano urtikarijo, tiščanje v prsih, piskanje v pljučih, hipotenzijo ter anafilaksijo.
English: IDELVION is a haemophilia medicine that replaces a natural blood clotting (coagulation) factor IX.
Slovenian: Zdravilo IDELVION je zdravilo za zdravljenje hemofilije, ki nadomešča naravni krvni faktor IX za strjevanje (koagulacijo) krvi.
English: Repeat every 24 - 72 hours for the first week, and then maintenance dose 1 - 2 times per week until bleeding stops and healing is achieved.
Slovenian: Ponovite vsakih 24 - 72 ur v prvem tednu, nato uvedite vzdrževalni odmerek 1-2 krat na teden, dokler krvavitev ne preneha in pride do celjenja.
English: The following side effects have been observed with IDELVION commonly (may affect up to 1 in 10 people):
Slovenian: Pri uporabi zdravila IDELVION so bili opaženi naslednji neželeni učinki pogosto (pojavijo se lahko pri največ 1 od 10 bolnikov):
English: 6 to <12 years (N=15)
Slovenian: 6 do <12 let (N=15)
English: Degree of Haemorrhage /
Slovenian: Stopnja krvavitve/
English: IDELVION remains intact in the circulation until factor IX is activated, whereupon albumin is cleaved, releasing activated factor IX (FIXa) when it is needed for coagulation.
Slovenian: Zdravilo IDELVION ostaja v obtoku nespremenjeno vse do aktivacije faktorja IX, pri čemer se albumin cepi in sprosti se aktivirani faktor IX (FIXa), ko je potreben za koagulacijo.
English: Major haemorrhage Life threatening haemorrhages, deep muscle bleeding including iliopsoas
Slovenian: Obsežnejša krvavitev Smrtno nevarne krvavitve, krvavitev globoko v mišico, vključno z mišico iliopsoas
English: If not used immediately, in-use storage times and conditions prior to use are in the responsibility of the user.
Slovenian: Če se zdravila ne uporabi takoj po rekonstituciji, je za trajanje in pogoje shranjevanja pred uporabo odgovoren uporabnik.
English: With the use of factor IX products obtained from CHO cells very rarely development of antibodies to hamster protein has been observed.
Slovenian: Z uporabo zdravil faktorja IX, pridobljenega iz celic CHO (celice jajčnika kitajskega hrčka - Chinese hamster ovary), so zelo redko opazili pojav protiteles proti proteinom hrčka.
English: PK simulations suggest the time to reach 5% plasma FIX activity following a single injection of 50 IU/kg IDELVION to be 7 days for 1-<6years, 9 days for 6-<12 years and 11 days for 12-<18 years of age).
Slovenian: Simulacije farmakokinetike nakazujejo, da je čas za dosego 5-odstotne plazemske aktivnosti faktorja IX po prejemu enkratne injekcije zdravila IDELVION 50 i.e./kg 7 dni za starostno skupino 1 - < 6 let, 9 dni za starostno skupino 6 - < 12 let in 11 dni za starostno skupino 12 - < 18 let.
English: IDELVION works by replacing factor IX in haemophilia B patients to enable their blood to clot.
Slovenian: Zdravilo IDELVION deluje tako, da nadomesti faktor IX pri bolnikih s hemofilijo B in omogoči strjevanje njihove krvi.
English: These include hives, generalised skin rash, tightness of the chest, wheezing, low blood pressure (hypotension), and anaphylaxis (a serious allergic reaction that causes severe difficulty in breathing, or dizziness).
Slovenian: Ti vključujejo koprivnico, kožne izpuščaje po vsem telesu, tiščanje v prsih, piskanje v pljučih, nizek krvni tlak (hipotenzija) ter anafilaksijo (resno alergijsko reakcijo, ki povzroči hude težave z dihanjem ali omotico).
English: IR = incremental recovery; AUC = area under the factor IX activity time curve; CL = body weight adjusted clearance; Elimination t1/2 = Elimination half-life
Slovenian: IR = povrnitev aktivnosti; AUC = površina pod krivuljo aktivnosti faktorja IX v odvisnosti od časa; CL = očistek, prilagojen na telesno maso; t1/2 izločanja = razpolovni čas izločanja
English: Bring the solvent to room temperature (below 25 °C).
Slovenian: Vehikel segrejte na sobno temperaturo (do 25 °C).
English: What IDELVION looks like and contents of the pack
Slovenian: Izgled zdravila IDELVION in vsebina pakiranja
English: Some patients who are well-controlled on a once-weekly regimen might be treated with up to 75 IU/kg on an interval of 10 or 14 days.
Slovenian: Nekateri bolniki, ki so dobro pod nadzorom z enkrat tedensko shemo odmerjanja, se lahko zdravijo z odmerkom do 75 i.e./kg v intervalu na 10 ali 14 dni.
English: • If you need a central venous access device (CVAD for injection of IDELVION), the risk of complications including local infections, bacteria in the blood (bacteremia) and the formation of a blood clot in the blood vessel (thrombosis) where the catheter is inserted should be considered by your doctor.
Slovenian: • Če je za injiciranje zdravila IDELVION potreben centralni venski kateter (CVK), mora zdravnik upoštevati možnost zapletov, kot so lokalne okužbe, prisotnost bakterij v krvi (bakteriemija) in nastanek krvnih strdkov v krvnih žilah (tromboza) na mestu vstavitve katetra.
English: The pharmacokinetics (PK) of IDELVION were evaluated following an intravenous injection of a single dose of 25, 50 and 75 IU/kg.
Slovenian: Farmakokinetika zdravila IDELVION je bila ovrednotena po intravenskem injiciranju enkratnih odmerkov 25, 50 in 75 i.e./kg.
English: Hypersensitivity to the active substance (recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)) or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost za učinkovino (rekombinantni fuzijski protein, sestavljen iz koagulacijskega faktorja IX, povezanega z albuminom (rIX-FP)) ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: • Because of the risk of allergic reactions with factor IX, your initial administration of IDELVION should be performed under medical observation where proper medical care for allergic reactions can be provided.
Slovenian: • Zaradi tveganja pojava alergijskih reakcij, povezanih s faktorjem IX, mora začetno dajanje zdravila IDELVION potekati pod zdravniškim nadzorom, kjer je mogoče zagotoviti ustrezno zdravstveno oskrbo alergijskih reakcij.
English: Some patients who are well-controlled on a once-weekly regimen might be treated with up to 75 IU/kg on an interval of 10 or 14 days (see section 5.1).
Slovenian: Nekateri bolniki, ki so dobro pod nadzorom z enkrat tedensko shemo odmerjanja, se lahko zdravijo z odmerkom do 75 i.e./kg v intervalu na 10 ali 14 dni (glejte poglavje 5.1).
English: • Allergic-type hypersensitivity reactions are possible and may include the following symptoms: hives, skin rashes (generalised urticaria), tightness of the chest, wheezing, low blood pressure (hypotension) and anaphylaxis (a serious reaction that causes severe difficulty in breathing or dizziness).
Slovenian: • možne so alergijske preobčutljivostne reakcije in lahko vključujejo naslednje simptome: koprivnica, kožni izpuščaji (generalizirana urtikarija), stiskanje v prsih, sopenje, nizek krvni tlak (hipotenzija) in anafilaksija (resna reakcija, ki povzroča hude težave z dihanjem ali omotičnost).
English: IDELVION was administered by bolus injection.
Slovenian: Zdravilo IDELVION je bilo dano z bolusno injekcijo.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeat dose toxicity, genotoxicity, thrombogenicity and local tolerability.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri enkratnih in ponavljajočih odmerkih, genotoksičnosti, trombogenosti in lokalnega prenašanja ne kažejo posebnega tveganja za človeka.
English: For routine prophylaxis the recommended dose regimen for paediatric subjects is 35 to 50 IU/kg once weekly (see sections 5.1 and 5.2).
Slovenian: Za rutinsko profilakso je priporočena shema odmerjanja pri pediatričnih bolnikih 35 do 50 i.e./kg enkrat na teden (glejte poglavje 5.1 in 5.2).
English: 1 filter transfer device 20/20
Slovenian: 1 priprava za prenos s filtrom 20/20
English: Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock).
Slovenian: V redkih primerih so opazili preobčutljivostne ali alergijske reakcije (ki lahko vključujejo angioedem, pekoči občutek in zbadanje na mestu infundiranja zdravila, mrzlico, pordelost, generalizirano urtikarijo, glavobol, koprivnico, hipotenzijo, letargijo, siljenje na bruhanje, nemirnost, tahikardijo, tiščanje v prsih, ščemenje, bruhanje in piskanje v pljučih), ki so v nekaterih primerih napredovale do hude anafilaksije (vključno s šokom).
English: Measurement with a one-stage clotting assay using a kaolin based aPTT reagent or Actin FS aPTT reagent will likely result in an underestimation of activity level.
Slovenian: Merjenje z enofaznim koagulacijskim testom, ki uporablja reagent za aPTČ (aktivirani parcialni tromboplastinski čas) na podlagi kaolina ali reagent za Actin FS aPTČ, bo najverjetneje povzročilo prenizko oceno koagulacijske aktivnosti.
English: Repeat every 24 - 72 hours for the first week, and then maintenance dose weekly until bleeding stops and healing is achieved.
Slovenian: Ponovite vsakih 24 - 72 ur v prvem tednu, nato uvedite vzdrževalni odmerek tedensko, dokler krvavitev ne preneha in pride do celjenja.
English: Pharmacokinetic (PK) parameters of IDELVION were evaluated in adolescents (12 to <18 years of age) and children (1 to <12 years of age) following an intravenous injection of a single dose of
Slovenian: Farmakokinetične parametre zdravila IDELVION so ovrednotili pri mladostnikih (starih 12 do <18 let) in otrocih (starih 1 do <12 let) po intravenskem injiciranju enkratnega odmerka 50 i.e./kg.
English: Cmax (IU/dl)
Slovenian: Cmax (i.e./dl)
English: Marketing Authorization Holder and Manufacturer
Slovenian: Imetnik dovoljenja za promet z zdravilom in izdelovalec
English: • Injection site reactions
Slovenian: • reakcije na mestu injiciranja.
English: Other ingredients: Tri-sodium citrate dihydrate, Polysorbate 80, Mannitol, Sucrose, HCl
Slovenian: Druge sestavine: trinatrijev citrat dihidrat, polisorbat 80, manitol, saharoza, HCl
English: PK simulations suggest the time to reach 5% plasma FIX activity following a single injection of 50 IU/kg IDELVION to be 12.5 days for adults.
Slovenian: Simulacije farmakokinetike nakazujejo, da je čas za dosego 5-odstotne plazemske aktivnosti faktorja IX po prejemu enkratne injekcije 50 i.e./kg zdravila IDELVION pri odraslih 12,5 dni.
English: Tri-sodium citrate dihydrate, polysorbate 80, mannitol, sucrose, and HCl (for pH adjustment) See last paragraph of section 2.
Slovenian: Trinatrijev citrat dihidrat, polisorbat 80, manitol, saharoza in HCl (za uravnavanje pH) Glejte zadnji odstavek poglavja 2.
English: After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Slovenian: Ob ponovnem zdravljenju z zdravili, ki vsebujejo humani koagulacijski faktor IX, moramo bolnike spremljati za možnost pojava nevtralizirajočih protiteles (inhibitorjev) in določati njihovo koncentracijo s primernimi biološkimi testi, ki podajajo koncentracijo v enotah Bethesda (Bethesda Units, BU).
English: If you use more IDELVION than you should Please contact your doctor immediately if you inject more IDELVION than your doctor recommends.
Slovenian: Če ste uporabili večji odmerek zdravila IDELVION, kot bi smeli Če ste injicirali večji odmerek zdravila IDELVION, kot ga je priporočil zdravnik, se čimprej posvetujte z zdravnikom.
English: The potency (International Units [IU]) is determined using an in-vitro activated partial thromboplastin time (aPTT)-based one-stage clotting assay calibrated against the World Health Organization (WHO) International Standard for factor IX concentrate.
Slovenian: Jakost (izražena v mednarodnih enotah [i.e.]) je določena s pomočjo enofaznega testa strjevanja krvi, ki temelji na in-vitro aktiviranem parcialnem tromboplastinskem času (aPTČ), ki je kalibriran po mednarodnem standardu Svetovne zdravstvene organizacije (WHO) za koncentrat faktorja IX.
English: Do not use IDELVION
Slovenian: Ne uporabljajte zdravila IDELVION
English: The efficacy of IDELVION has been evaluated in the open-label, uncontrolled part of a phase 2/3 study, in which a total of 63 male, previously treated patients (PTPs) between 12 and 61 years of age received IDELVION either for prophylaxis once every 7-, 10- and/or 14-day intervals and/or for the treatment of bleeding episodes on an on-demand basis.
Slovenian: Učinkovitost zdravila IDELVION je bila ovrednotena v odprtem, nenadzorovanem delu študije faze 2/3, v kateri je skupno 63 predhodno zdravljenih preiskovancev moškega spola, starih od 12 do 61 let, prejelo zdravilo IDELVION za profilakso enkrat na 7-, 10- in/ali 14-dni in/ali za zdravljenje epizod krvavitev po potrebi.
English: MARKETING AUTHORIZATION NUMBER(S)
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
English: IR (IU/dl)/(IU/kg)
Slovenian: IR (i.e./dl)/(i.e./kg)
English: General instructions - The reconstituted solution should be clear or slightly opalescent, yellow to colourless.
Slovenian: - Rekonstituirana raztopina mora biti bistra ali nekoliko opalescentna, rumena do brezbarvna.
English: Type of surgical procedure
Slovenian: vrsta kirurškega posega
English: PK parameters (presented below) were estimated based on the plasma factor IX activity over time profile measured by the one-stage clotting assay.
Slovenian: Farmakokinetični parametri (predstavljeni spodaj) so bili ocenjeni na podlagi profila aktivnosti faktorja IX v plazmi v odvisnosti od časa, izmerjenega z enofaznim koagulacijskim testom.
English: Up to 25.8 mg (1.13 mmol) sodium per dose (bodyweight 70 kg).
Slovenian: Do 25,8 mg (1,13 mmol) natrija na odmerek (telesna masa 70 kg).
English: Powder: Tri-sodium citrate dihydrate, Polysorbate 80, Mannitol, Sucrose, HCl (for pH adjustment).
Slovenian: Prašek: Trinatrijev citrat dihidrat, polisorbat 80, manitol, saharoza, HCl (za uravnavanje pH).
English: A phase 1/2 study evaluated the treatment efficacy and prevention of bleeding episodes of rIX-FP in 17 subjects (ages 13-46 years), 13 subjects in the prophylaxis arm received weekly prophylaxis with IDELVION for approximately 11 months, and 4 subjects in the on-demand arm received IDELVION upon occurrence of bleeding events.
Slovenian: V študiji faze 1/2 so ovrednotili učinkovitost zdravljenja in preprečevanje krvavitev z rIX-FP pri 17 preiskovancih (starih 13 - 46 let), 13 preiskovancih, vključenih v krak s profilaktičnim zdravljenjem, ki so prejemali tedensko profilakso z zdravilom IDELVION približno 11 tednov, in 4 preiskovancih v kraku študije, ki so prejemali zdravilo IDELVION po potrebi ob pojavu krvavitev.
English: Albutrepenonacog alfa is a purified protein produced by recombinant DNA technology, generated by the genetic fusion of recombinant albumin to recombinant coagulation factor IX.
Slovenian: Albutrepenonakog alfa je prečiščena beljakovina, pridobljena s tehnologijo rekombinantne DNK, ki nastane z gensko fuzijo rekombinantnega albumina na rekombinantni koagulacijski faktor IX.
English: Prophylaxis and control of bleeding in PTPs below 12 years The efficacy of IDELVION has been evaluated in a phase 3 study, in which a total of 27 male PTPs between 1 and 10 years (median age 6.0 years) with 12 patients < 6 years, received IDELVION for prophylaxis and control of bleeding episodes.
Slovenian: Profilaksa in obvladovanje krvavitev pri predhodno zdravljenih bolnikih, mlajših od 12 let Učinkovitost zdravila IDELVION je bila ocenjena v študiji faze 3, v kateri je skupno 27 predhodno zdravljenih preiskovancev moškega spola, starih od 1 do 10 let (mediana 6,0 let), pri čemer je bilo 12 bolnikov starih < 6 let, prejelo zdravilo IDELVION za profilakso in nadzor epizod krvavitev.
English: When using an in vitro thromboplastin time (aPTT)-based one stage clotting assay for determining Factor IX activity in patients' blood samples, plasma factor IX activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay.
Slovenian: Pri določanju aktivnosti faktorja IX v krvi bolnikov z in vitro enostopenjskim testom strjevanja na osnovi aktiviranega parcialnega tromboplastinskega časa (aPTČ), lahko na aktivnost faktorja IX v plazmi pomembno vplivata tako vrsta reagenta za aPTČ kot tudi referenčni standard, ki se uporablja v testu.
English: Ensure product and solvent vial flip caps are removed and the stoppers are treated with an antiseptic solution and allowed to dry prior to opening the Mix2Vial package.
Slovenian: Prepričajte se, da sta zunanji zaščitni zaporki viale s praškom in viale z vehiklom odstranjeni, zamaška pa obrisana z aseptično raztopino in osušena še pred odprtjem zavoja Mix2Vial.
English: There are insufficient data to provide information on inhibitor incidence in PUPs.
Slovenian: Ni dovolj podatkov, da bi lahko posredovali informacije o pogostosti pojavljanja inhibitorja pri predhodno nezdravljenih bolnikih.
English: A peak level of 50 % of normal is required in a 80 kg patient with severe haemophilia B. The appropriate dose would be 80 kg x 50 IU/dl x 0.77 dl/kg = 3080 IUs.
Slovenian: Najvišja raven, ki je 50 % normalne vrednosti, je potrebna pri bolniku s telesno maso 80 kg in hudo hemofilijo B. Ustrezen odmerek bi bil 80 kg x 50 i.e./dl x 0,77 dl/kg = 3080 i.e.
English: There is a potential risk of thromboembolic episodes following the administration of factor IX products, with a higher risk for low purity preparations.
Slovenian: Pri uporabi zdravil faktorja IX obstaja tveganje za nastanek tromboemboličnih dogodkov, ki je večje pri pripravkih majhne čistote.
English: Carefully remove the blister package from the Mix2Vial set by holding at the rim, and pulling vertically upwards.
Slovenian: Previdno odstranite pretisni omot s seta Mix2Vial, tako da ga primete za obod in potegnete navpično navzgor.
English: With one hand grasp the powder-side of the Mix2Vial set and with the other hand grasp the solvent-side and unscrew the set carefully counterclockwise into two pieces.
Slovenian: Z eno roko primite set Mix2Vial na tisti strani, kjer je viala s praškom, z drugo pa na strani vehikla in z odvijanjem v nasprotni smeri urinega kazalca previdno razstavite set na dva dela.
English: This medicinal product contains up to 25.8 mg (1.13 mmol) sodium per dose (bodyweight 70 kg) if the maximal dose (15 ml = 6000 IU) is applied.
Slovenian: To zdravilo vsebuje do 25,8 mg (1,13 mmol) natrija na odmerek (telesna masa 70 kg), če je uporabljen največji odmerek (15 ml = 6000 i.e.).
English: IDELVION contains sodium
Slovenian: Zdravilo IDELVION vsebuje natrij
English: Factor IX activity is absent or greatly reduced in patients with haemophilia B and substitution therapy may be required.
Slovenian: Pri bolnikih s hemofilijo B je aktivnost faktorja IX odstotna ali močno zmanjšana in potrebno je lahko nadomestno zdravljenje.
English: Including uncomplicated tooth extraction
Slovenian: Manjši kirurški poseg vključno z nezapletenim izdrtjem zoba
English: The PK parameters following a single injection of 50 IU/kg IDELVION (see table below) were based on plasma factor IX activity measured by the one-stage clotting assay.
Slovenian: Farmakokinetični parametri po enkratnem injiciranju 50 i.e./kg zdravila IDELVION (glejte preglednico spodaj) so temeljili na aktivnosti faktorja IX v plazmi, izmerjeni z enofaznim testom strjevanja.
English: IDELVION 250 IU powder and solvent for solution for injection IDELVION 500 IU powder and solvent for solution for injection IDELVION 1000 IU powder and solvent for solution for injection IDELVION 2000 IU powder and solvent for solution for injection Albutrepenonacog alfa
Slovenian: IDELVION 250 i.e. prašek in vehikel za raztopino za injiciranje IDELVION 500 i.e. prašek in vehikel za raztopino za injiciranje IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje IDELVION 2000 i.e. prašek in vehikel za raztopino za injiciranje albutrepenonakog alfa
English: IDELVION 2000 IU
Slovenian: IDELVION 2000 i.e.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton administration set (inner box)
Slovenian: škatla s setom za dajanje (notranja škatla)
English: ATC code: B02BD04
Slovenian: Farmakoterapevtska skupina: antihemoragiki, koagulacijski faktor IX Oznaka ATC: B02BD04
English: 1 disposable 5 ml syringe 1 venipuncture set 2 alcohol swabs 1 non-sterile plaster
Slovenian: 1 komplet za punkcijo vene 2 alkoholni blazinici 1 nesterilen obliž
English: Required dose (IU) = body weight (kg) x desired factor IX rise (% of normal or IU/dl) x {reciprocal of observed recovery (IU/kg per IU/dl)}
Slovenian: Potrebni odmerek (i.e.) = telesna masa (kg) x želeni dvig faktorja IX (% normalne vrednosti ali i.e/dl) x {obratna vrednost ugotovljene povrnitve aktivnosti (i.e./kg na i.e./dl)}
English: What is IDELVION?
Slovenian: Kaj je zdravilo IDELVION?
English: The IDELVION solution must not be diluted.
Slovenian: Raztopine zdravila IDELVION ne smemo redčiti.
English: Subjects who received prophylactic treatment started with 35-50 IU/kg once weekly.
Slovenian: Začetni odmerek pri preiskovancih, ki so prejemali profilaktično zdravljenje, je bil 35-50 i.e./kg enkrat na teden.
English: A dose of 2000 IUs of IDELVION, administered to a 80 kg patient, should be expected to result in a peak post-injection factor IX increase of 2000 IUs x 1.3 (IU/dl per IU/kg) /80 kg = 32.5 IU/dl (32.5 % of normal).
Slovenian: Za odmerek 2000 i.e. zdravila IDELVION, uporabljen pri bolniku s telesno maso 80 kg, se pričakuje, da po injiciranju povzroči najvišje zvišanje ravni faktorja IX za 2000 i.e. x 1,3 (i.e./dl na i.e./kg)/80 kg = 32,5 i.e./dl (32,5 % normalne vrednosti).
English: For an incremental recovery of 1.3 IU/dl per 1 IU/kg, the dose is calculated as follows: Dose (IU) = body weight (kg) x desired factor IX increase (IU/dl) x 0.77 dl/kg
Slovenian: Za postopno povrnitev aktivnosti 1,3 i.e./dl na 1 i.e./kg, se odmerek izračuna kot sledi: Odmerek (i.e.) = telesna masa (kg) x želeno zvišanje ravni faktorja IX (i.e./dl) x 0,77 dl/kg
English: IDELVION contains up to 25.8 mg (1.13 mmol) sodium per dose (bodyweight 70 kg) if the maximal dose (15 ml = 6000 IU) is applied.
Slovenian: Zdravilo IDELVION vsebuje do 25,8 mg (1,13 mmol) natrija na odmerek (telesna masa 70 kg) če je uporabljen največji odmerek (15 ml = 6000 i.e.).